Deucravacitinib in moderate-to-severe psoriasis. Immunotherapy 2022 Nov;14(16):1279-1290
Date
11/15/2022Pubmed ID
36373503DOI
10.2217/imt-2022-0109Scopus ID
2-s2.0-85142918537 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Psoriasis is a chronic inflammatory disease that affects up to 1 in 20 people worldwide. A patient's quality of life and health can be drastically affected by psoriasis. The number of therapies for patients with moderate to severe psoriasis has steadily grown over the past two decades, with biologic immunotherapies being the primary agents developed. However, new small-molecule oral therapies have lagged in development. Deucravacitinib is an oral small molecule that inhibits the activity of TYK2, a member of the JAK family. Deucravacitinib works by allosterically inhibiting TYK2, increasing the specificity of this agent for TYK2 rather than other members of this kinase family. Deucravacitinib has demonstrated safety and efficacy in moderate to severe plaque psoriasis in clinical trial development, with >50% of patients on deucravacitinib 6 mg daily achieving ≥75% reduction in Psoriasis Area and Severity Index score from baseline at 16 weeks versus 9-13% on placebo and 35-41% on apremilast 30 mg twice daily in phase III clinical trials.
Author List
Vu A, Maloney V, Gordon KBAuthor
Kenneth Brian Gordon MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Chronic DiseaseDouble-Blind Method
Humans
Psoriasis
Quality of Life
Treatment Outcome
